DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Roluperidone
Roluperidone
Clinical Expertise and Patient Focus November, 2019
Minerva Neurosciences Announces the Results
“Indagandis Sedibus Et Causis Morborum” Potential Conflicts of Interest (January 2016 to Present)
GPCR/G Protein
Roluperidone (MIN-101)
Negative Symptoms of Schizophrenia
Financial Results for the First Three Months of the Fiscal Year Ending March 31, 2019 (IFRS, Consolidated)
Zachary Prensky, Chief Executive Officer & Co-Founder
Cannabis and Psychosis … Genetics Continuum … Neurogenesis and Schizophrenia … Treatment-Refractory Schizophrenia … Stigma …
Stembook 2018.Pdf
Novel and Emerging Treatments for Schizophrenia: Beyond Postsynaptic Dopamine Receptor Blockade Christoph U Correll
5-HT Receptor Serotonin Receptor;5-Hydroxytryptamine Receptor
Advances in the Treatment of Schizophrenia: Integrating New and Emerging Options Into Therapy to Meet Unmet Needs
ACNP 57Th Annual Meeting: Poster Session I
CNS SPECTRUMS CME Review Article Keeping up with the Clinical Advances: Schizophrenia
1500 T 7 Minerva Neurosciencs.Pptx
Lääkeaineiden Yleisnimet (INN-Nimet) 31.12.2019
Vl Newron Valuation Report
Top View
New Treatments for Schizophrenia
Morphing of Ibogaine: a Successful Attempt Into the Search for Sigma-2 Receptor Ligands
CNS SPECTRUMS CME Review Article Keeping up with the Clinical Advances: Schizophrenia
Bioactive Compound Library Plus (96-Well)
Cambridge University Press 978-1-108-83857-3 — Stahl's Essential Psychopharmacology Stephen M
5-HT Receptor Serotonin Receptor; 5-Hydroxytryptamine Receptor
Drug Repurposing Compound Library Plus (96-Well)
Do DSM Classification Hep Or Hinder Drug Development?
Neuronal Signaling
Negative Symptoms of Schizop AN
2 Receptor and Its Role in Cancer with Focus on a Multitarget Directed Ligand (MTDL) Approach
Drug Repurposing Compound Library (96-Well)
Inthought Master Template
Improving the Lives of Patients with Schizophrenia: Therapeutic Updates and Considerations for Comprehensive, Multidisciplinary Care
Disclosure No Conflicts of Interest to Disclose
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri